"Immunotoxins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
| Descriptor ID |
D000922
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.450 D12.776.377.715.548.114.580.450 D27.888.569.271
|
| Concept/Terms |
Immunotoxins- Immunotoxins
- Cytotoxin-Antibody Conjugates
- Conjugates, Cytotoxin-Antibody
- Cytotoxin Antibody Conjugates
- Immunotoxin
- Antibody-Toxin Hybrids
- Antibody Toxin Hybrids
- Hybrids, Antibody-Toxin
- Affinotoxins
- Antibody-Toxin Conjugates
- Antibody Toxin Conjugates
- Conjugates, Antibody-Toxin
- Toxin-Antibody Conjugates
- Conjugates, Toxin-Antibody
- Toxin Antibody Conjugates
- Toxin-Antibody Hybrids
- Hybrids, Toxin-Antibody
- Toxin Antibody Hybrids
- Monoclonal Antibody-Toxin Conjugates
- Antibody-Toxin Conjugates, Monoclonal
- Conjugates, Monoclonal Antibody-Toxin
- Monoclonal Antibody Toxin Conjugates
Toxins, Chimeric- Toxins, Chimeric
- Chimeric Toxins
- Toxin Conjugates
- Conjugates, Toxin
- Toxin Carriers
- Carriers, Toxin
- Toxin Conjugate
- Conjugate, Toxin
- Chimeric Toxin
- Toxin, Chimeric
- Toxin Carrier
- Carrier, Toxin
|
Below are MeSH descriptors whose meaning is more general than "Immunotoxins".
Below are MeSH descriptors whose meaning is more specific than "Immunotoxins".
This graph shows the total number of publications written about "Immunotoxins" by people in this website by year, and whether "Immunotoxins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotoxins" by people in Profiles.
-
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020 01; 80(1):99-108.
-
Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, Hassan R. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clin Cancer Res. 2017 Mar 15; 23(6):1564-1574.
-
Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget. 2014 Oct 15; 5(19):9460-71.
-
Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med. 2013 Feb; 7(1):23-35.
-
Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW, Akintoye SO, DiRienzo JM. Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res. 2011 May; 90(5):638-45.
-
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 01; 64(17):6200-6.
-
Kernan NA, Byers V, Scannon PJ, Mischak RP, Brochstein J, Flomenberg N, Dupont B, O'Reilly RJ. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. JAMA. 1988 Jun 03; 259(21):3154-7.